摘要
Main text In the past decades,there have been several studies con-cerning the efficacy of sequencing of chemotherapy on disease control and survival in locoregionally advanced(LA)nasopharyngeal carcinoma(NPC).The addition of concurrent cisplatin to radiotherapy has demonstrated survival improvements that are attributable to both dis-tant metastasis and locoregional control.Specific to the latter,the advent of intensity-modulated radiotherapy has resulted in superior tumor control given the bet-ter dosimetry compared to conventional techniques[1].However,distant recurrence still occurs in 20-30%patients and accounts for the main cause of death.To address this,several groups have explored the advantages of adding neoadjuvant chemotherapy(NACT)or adju-vant chemotherapy(ACT)to the backbone of concurrent chemoradiotherapy(CCRT).
基金
MC reports personal fees from Astellas,personal fees from Janssen,grants and personal fees from Ferring,non-financial support from Astrazeneca,personal fees and non-financial support from Varian,grants from Sanofi Canada,grants from GenomeDx Biosciences,non-financial support from Medlever,outside the submitted work
MC is supported by the National Medical Research Council Singapore Clinician-Scientist Award-#NMRC/CSA/0027/2018
the Duke-NUS Oncology Academic Program Proton Research Program
This work was supported by grants from the National Key R&D Program of China(2017YFC0908500,2017YFC1309003)
the National Natural Science Foundation of China(No.81425018,No.81672868,No.81602371).
